obeticholic acid
Drug data last refreshed Yesterday
OCALIVA (obeticholic acid) is an oral tablet approved by the FDA on May 27, 2016, as a novel therapeutic agent for cholestatic liver diseases. The mechanism of action and specific indications are not detailed in the available data, but the product operates as a small-molecule NDA drug. OCALIVA represents an important treatment option in hepatology, addressing a significant unmet need in a specialized therapeutic area with limited competition.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Linerixibat and Obeticholic Acid Drug Interaction Study in Healthy Adult Participants
Obeticholic Acid Versus Placebo, in Combination with Ursodeoxycholic Acid in Patients with Primary Biliary Cirrhosis
Study of Obeticholic Acid(OCA) Combination With Ursodeoxycholic Acid (UDCA) in Patients With Primay Biliary Cirrhosis (PBC)
Linerixibat and Obeticholic Acid Drug Interaction Study in Healthy Subjects
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
$164M Medicare spend — this is a commercially significant brand
OCALIVA's peak lifecycle stage and specialized indication profile create opportunities for field sales representatives, hepatology-focused medical science liaisons, and commercial managers experienced in rare/orphan disease marketing. Success on this product requires deep therapeutic knowledge of cholestatic liver diseases, strong relationships with hepatology specialists, and ability to navigate complex reimbursement landscapes. Currently, zero open positions are linked to OCALIVA in available job tracking data, suggesting stable commercial staffing or potential future expansion opportunities.
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/mo